Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
NCT07503808Phase 1Recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Feb 2026
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of IDE034 in Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Serous Ovarian Carcinoma (HGSOC), head and neck squamous cell carcinoma (HNSCC) and 5 more (2 arms), sponsored by IDEAYA Biosciences. Primary endpoints: Safety and tolerability of IDE034 at 20 months and Preliminary anti-tumor activity of IDE034 at 20 months. Started Feb 2026; status: recruiting.
02
Drugs
IDE034
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)High-Grade Serous Ovarian Carcinoma (HGSOC)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07503808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503808.